Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 13, Issue 4, 2003, Pages 435-443

  Melichar, B ^a   Savary, C A ^a   Patenia, R ^a   Templin, S ^a   Melicharova, K ^a   Freedman, Ralph S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytotoxicity; Monocytes; Ovarian cancer

Indexed keywords

CARBOPLATIN; CD14 ANTIGEN; CD16 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD64 ANTIGEN; CD86 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; MEMBRANE ANTIGEN; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; THYMIDINE DERIVATIVE; TRITIUM;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; BLOOD; CANCER CELL CULTURE; CANCER PATIENT; CELL ACTIVATION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; EPITHELIUM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCYTE; OVARY CARCINOMA; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ASCITIC FLUID; CARCINOMA; CULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; MACROPHAGE ACTIVATION; MACROPHAGES; MIDDLE AGED; MONOCYTES; OVARIAN NEOPLASMS; PHENOTYPE; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1242316943     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13331.x     Document Type: Article

References (56)

1. Freedman RS, Tomasovic B, Templin S et al. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Meth 1994;197:145-60.
2. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukocyte Biol 2001;69:11-20.
3. Schuman RR. Function of lipopolysaccharide (LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review. Res Immunol 1992;143:11-5.
4. Musso T, Deaglio S, Franco L et al. CD38 expression and functional activities are up-regulated by IFN-g on human monocytes and monocytic cell lines. J Leukocyte Biol 2001;69:605-12.
5. Rothe G, Gabriel H, Kovacs E et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers of hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996;16:1437-47.
6. Szeberenyi JB, Rothe G, Pallinger E, Orso E, Falus A, Schmitz G. Multi-color analysis of monocyte and dendritic cell precursor heterogeneity in whole blood. Immunobiology 2000;202:51-8.
7. Saleh MN, Goldman SJ, LoBuglio AF et al. CD16+ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. Blood 1995;85:2910-7.
8. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Invest 2001;61:363-70.
9. Melichar B, Touskova M, Dvorak J, Jandik P, Kopecky O. The peripheral blood leukocyte phenotype in patients with breast cancer. Effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacol Immunotoxicol 2001;23:163-73.
10. Hibbs JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity. Role of L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987;235:473-6.
11. Pace JL, Russel SW, Torres BA, Johnson HM, Gray PW. Recombinant mouse γ interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 1983;130:2011-3.
12. Cox GW, Melillo G, Chattopahyay U, Mullet D, Fertel RH, Varesio L. Tumor necrosis factor-α -dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced macrophage tumoricidal activity. J Immunother 1992;149:3290-6.
13. Fidler IJ. Therapy of cancer metastasis by systemic activation of macrophages. Adv Pharmacol 1994;30:271-326.
14. Hori K, Ehrke MJ, Mace K, Mihich E. Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: Synergism between tumor necrosis factor and g-interferon. Cancer Res 1987;47:5868-74.
15. Espinoza-Delgado I, Bosco MC, Musso T, Gusella GL, Longo DL, Varesio L. Interleukin-2 and human monocyte activation. J Leukocyte Biol 1995;57:13-9.
16. Malkovsky M, Loveland B, North M et al. Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature 1987;325:262-5.
17. Muenchen HJ, Aggarwal SK. Activation of murine peritoneal macrophages after cisplatin and taxol combination. Anti-Cancer Drugs 1997;8:784-9.
18. Ranjan P, Sodhi A, Sristava A. Cisplatin and interferon-γ treated murine macrophages induce apoptosis in tumor cell lines. Anti-Cancer Drugs 1997;8:797-806.
19. Manthey CL, Perera PY, Salkowski CA, Vogel SN. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994;152:825-31.
20. Melichar B, Savary C, Kudelka AP et al. Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799-809.
21. Freedman RS, Bowen JM, Leibovitz A et al. Characterization of an ovarian carcinoma cell line. Cancer 1978;42:2352-9.
22. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, Freedman RS. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res 1998;4:3069-76.
23. Koski IR, Poplack DG, Blaese RM. A nonspecific esterase stain for the identification of monocytes and macrophages. In: Bloom, BR, David, JR, eds. In: Vitro Methods in Cell-Mediated and Tumor Immunity. New York: Academic Press, 1976: 359-62.
24. Melichar B, Freedman RS. Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 2002;12:3-17.
25. Pujade-Lauraine E, Guastalla JP, Colombo N et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343-50.
26. Edwards RP, Gooding W, Lembersky BC et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399-407.
27. Betjes MGH, Tuk CW, Struijk DG, Krediet RT, Arisz L, Beelen RHJ. Antigen-presenting capacity of macrophages and dendritic cells in the peritoneal cavity of patients treated with peritoneal dialysis. Clin Exp Immunol 1993;94:377-84.
28. Kubicka U, Olszewski WL, Tarnowski W, Bielecki K, Ziolkowska A, Wierzbicki Z. Normal human immune peritoneal cells. Subpopulations and functional characteristics. Scand J Immunol 1996;44:157-63.
29. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukocyte Biol 2000;67:2-17.
30. Eischen A, Duclos B, Schmitt-Goguel M et al. Human resident peritoneal macrophages. phenotype and biology. Br J Haematol 1994;88:712-22.
31. Mathew G, Watson DI, Ellis TS, Jamieson GG, Rofe AM. The role of peritoneal immunity and the tumour-bearing state on the development of wound and peritoneal metastases after laparoscopy. Aust N Z J Surg 1999;69:14-8.
32. Dong Z, Yoneda J, Kumar R, Fidler IJ. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony stimulating factor. J Exp Med 1998;188:755-63.
33. Gagliardi MC, De Petrillo G, Salemi S et al. P-resentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro. Int Immunol 1995;7:1741-52.
34. Spiteri MA, Poulter LW. Characterization of immune inducer and suppressor macrophages from the normal lung. Clin Exp Immunol 1991;83:157-62.
35. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96.
36. Peters JH, Gieseler R, Thiele B, Steinbach F. Dendritic cells: from ontogenic orphans to myelomonocytic descendants. Immunol Today 1996;17:273-8.
37. Lopez M, Fechtenbaum J, David B et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992;11:209-17.
38. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992;7:265-70.
39. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukocyte Biol 1994;55:410-22.
40. Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukocyte Biol 1996;59:505-11.
41. Robertson MJ, Cameron C, Atkins MB et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999;5:9-16.
42. Lenzi R, Rosenblum M, Verschraegen C et al. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res 2002;8:3686-95.
43. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-I2. J of Immunother 2003;26(3):270-276.
44. Bernasconi S, Matteucci C, Sironi M et al. Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. Int J Cancer 1995;60:300-7.
45. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes. Regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993;178:669-74.
46. Imaizumi K, Kawabe T, Ichiyama S et al. Enhancement of tumoricidal activity of alveolar macrophages via CD40-CD40 ligand interaction. Am J Physiol 1999;277: L49-L57.
47. Vonderheide RH, Dutcher JP, Anderson JE et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 2001;19:3280-7.
48. Hwu P, Freedman RS. The immunotherapy of ovarian cancer. J Immunother 2002;in press.
49. Toner GC, Gabrilove JL, Gordon M et al. Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor. J Immunother 1994;15:59-66.
50. Modolell M, Corraliza IM, Link F, Soler G, Eichman K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mose bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995;25:1101-4.
51. Weinberg JB, Misukonis MA, Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS). Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184-95.
52. Gottlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 1992;4:385-90.
53. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10 producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999;163:6251-60.
54. Melichar B, Touskova M, Tosner J, Kopecky O. The phenotype of ascitic fluid lymphocytes in patients with ovarian carcinoma and other primaries. Onkologie 2001;24:156-60.
55. Freedman RS, Gibbons JA, Gledlin M, Kudelka AP, Kavanagh JJ, Edwards CL, Carrasco CH, Nash MA, Platsoucas CD. Immunopharmacology and cytokine production of a low dose schedule of intraperitoneally administered human recombinant interleukin-2 in patients with advanced epithelial ovarian carcinoma. J Immunother 1996;19:443-451.
56. Freedman RS, Kudelka AP, Kavanagh JJ et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin-2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinomatosis. Clin Cancer Res 2000;6:2268-78.